EA200870130A1 - Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 - Google Patents

Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6

Info

Publication number
EA200870130A1
EA200870130A1 EA200870130A EA200870130A EA200870130A1 EA 200870130 A1 EA200870130 A1 EA 200870130A1 EA 200870130 A EA200870130 A EA 200870130A EA 200870130 A EA200870130 A EA 200870130A EA 200870130 A1 EA200870130 A1 EA 200870130A1
Authority
EA
Eurasian Patent Office
Prior art keywords
complex
antibodies against
alpha receptor
preventing bonding
present
Prior art date
Application number
EA200870130A
Other languages
English (en)
Russian (ru)
Inventor
Джеффри С. Вэй
Стефен Д. Джиллис
Кин-Минь Ло
Юань Лью
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200870130A1 publication Critical patent/EA200870130A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
EA200870130A 2005-12-30 2006-12-19 Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 EA200870130A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75538305P 2005-12-30 2005-12-30
PCT/EP2006/012236 WO2007076927A1 (en) 2005-12-30 2006-12-19 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130

Publications (1)

Publication Number Publication Date
EA200870130A1 true EA200870130A1 (ru) 2009-02-27

Family

ID=37950573

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870130A EA200870130A1 (ru) 2005-12-30 2006-12-19 Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6

Country Status (16)

Country Link
US (2) US7820155B2 (https=)
EP (1) EP1966244B1 (https=)
JP (1) JP2009521909A (https=)
KR (1) KR20080090484A (https=)
CN (1) CN101346395A (https=)
AT (1) ATE550353T1 (https=)
AU (1) AU2006332216A1 (https=)
BR (1) BRPI0620797A2 (https=)
CA (1) CA2635615A1 (https=)
DK (1) DK1966244T3 (https=)
EA (1) EA200870130A1 (https=)
ES (1) ES2382164T3 (https=)
PL (1) PL1966244T3 (https=)
PT (1) PT1966244E (https=)
WO (1) WO2007076927A1 (https=)
ZA (1) ZA200806610B (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2551915C (en) * 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8153128B2 (en) * 2006-11-30 2012-04-10 Medimmune Limited Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
WO2009109584A1 (en) * 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EA019512B1 (ru) * 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
AU2009296937B2 (en) * 2008-09-29 2015-02-12 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods, and uses
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CA2744400C (en) * 2008-11-25 2019-01-15 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2421896A1 (en) 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
EP2464666B1 (en) * 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
AU2010278067B2 (en) * 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
ES2622487T3 (es) * 2009-08-19 2017-07-06 Merck Patent Gmbh Anticuerpos para la detección de complejos de integrina en material FFPE
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US20140255405A1 (en) 2011-05-27 2014-09-11 Dutalys Removal of Monomeric Targets
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20140315956A1 (en) * 2011-07-29 2014-10-23 Nationwide Children's Hospital Small molecule inhibitors of il-6 and uses thereof
WO2013059548A1 (en) * 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US9816989B2 (en) 2013-03-12 2017-11-14 Institute of Arthritis Research, LLC Immunologically active polypeptide
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
CN103897061B (zh) * 2014-03-25 2017-06-16 宝船生物医药科技(上海)有限公司 阻断西妥昔单抗和egfr结合的抗体、其试剂盒及杂交瘤细胞
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
PT3215530T (pt) * 2014-11-07 2019-11-21 Sesen Bio Inc Anticorpos de il-6 melhorados
LT3226888T (lt) * 2014-12-01 2021-05-25 Ferring B.V. Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
RS65665B1 (sr) * 2014-12-01 2024-07-31 Ferring Bv Selektivne kompozicije inhibitora il-6-trans-signalizacije
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN111057152B (zh) * 2019-12-11 2022-03-11 中国人民解放军第四军医大学 一种抗人IL-6Ra单克隆抗体及其应用
JP2023042974A (ja) * 2021-09-15 2023-03-28 シスメックス株式会社 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体
CN119080929B (zh) * 2023-06-05 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800829B2 (en) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
EP1572103A4 (en) 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
WO2004071404A2 (en) 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130

Also Published As

Publication number Publication date
ES2382164T3 (es) 2012-06-05
JP2009521909A (ja) 2009-06-11
US20110038877A1 (en) 2011-02-17
US20070178098A1 (en) 2007-08-02
ZA200806610B (en) 2009-11-25
PL1966244T3 (pl) 2012-08-31
KR20080090484A (ko) 2008-10-08
CA2635615A1 (en) 2007-07-12
US7820155B2 (en) 2010-10-26
ATE550353T1 (de) 2012-04-15
WO2007076927A1 (en) 2007-07-12
CN101346395A (zh) 2009-01-14
PT1966244E (pt) 2012-05-17
DK1966244T3 (da) 2012-04-23
AU2006332216A1 (en) 2007-07-12
BRPI0620797A2 (pt) 2011-11-22
US8536308B2 (en) 2013-09-17
EP1966244A1 (en) 2008-09-10
EP1966244B1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
ATE465181T1 (de) Humanisierte anti-cmet-antagonisten
EA201170323A1 (ru) Антитела против il-12/il-23
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
EA200800812A1 (ru) Композиции антитела против cd3
TNSN08502A1 (en) High affinity antibodies to human il-6 receptor
DE602006013029D1 (de) Anti-egfr-antikörper
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201100694A1 (ru) Антитело к cd38 человека и его применение
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
UA109633C2 (uk) Антитіло людини проти тканинного фактора
RU2009108148A (ru) Иммуноглобулины
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
MX380702B (es) Proteinas de union al antigeno del receptor de oncostatina m.
NO20061412L (no) Terapi av okulaere foretyrrelser
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2007033140A3 (en) Prok2 antagonists and methods of use
NO20065473L (no) IL-6RL/IL-6-kimaerer for terapi av kjemoterapeutisk indusert perifer nevropati.
DK1730196T3 (da) EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его